8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 12, 2026·SEC
MacroGenics, Inc.(MGNX)Earnings, Financials & Key Ratios
MGNX•NASDAQ
Price updated Jun 19, 2026
AboutMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Show more
- Revenue$150M+0.8%
- EBITDA-$66M+36.3%
- Net Income-$75M-11.4%
- EPS (Diluted)-1.18-10.3%
- Gross Margin71.12%-22.5%
- EBITDA Margin-43.93%+36.8%
- Operating Margin-48.72%+34.6%
- Net Margin-49.91%-10.6%
- ROE-86.95%-74.4%
MGNX Key Insights
MacroGenics, Inc. (MGNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MGNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MGNX Price & Volume
MacroGenics, Inc. (MGNX) stock price & volume — 10-year historical chart
Loading chart...
MGNX Growth Metrics
MacroGenics, Inc. (MGNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.01%
5 Years8.87%
3 Years-0.12%
TTM3.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-23.6%
Return on Capital
10 Years-46.47%
5 Years-54.19%
3 Years-51.22%
Last Year-34.7%
MGNX Recent Earnings
MacroGenics, Inc. (MGNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.58-1.8%
$0.57
Rev
$21M+36.3%
$15M
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$0.58-1.8%
$0.57
Rev
$21M+36.3%
$15M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.22+47.6%
$0.42
Rev
$41M+19.2%
$35M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.27+156.3%
$0.48
Rev
$73M+161.9%
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.58vs $0.57-1.8% | $21Mvs $15M+36.3% |
| Q2 2026 | May 13, 2026 | $0.58vs $0.57-1.8% | $21Mvs $15M+36.3% |
| Q2 2026 | Mar 9, 2026 | $0.22vs $0.42+47.6% | $41Mvs $35M+19.2% |
| Q4 2025 | Nov 12, 2025 | $0.27vs $0.48+156.3% | $73Mvs $28M+161.9% |
Based on last 12 quarters of dataView full earnings history →
MGNX Peer Comparison
MacroGenics, Inc. (MGNX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 ZYME | 1.7B | 23.14 | -21.43 | 38.87% | -126.33% | -0.25% | 0.07 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% |
Compare MGNX vs Peers
MacroGenics, Inc. (MGNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGNX Income Statement
MacroGenics, Inc. (MGNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 155.52M | 60.12M | 62.02M | 97.76M | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M | 157.08M |
Revenue Growth % | 79.62% | -61.34% | 3.17% | 57.62% | -22.63% | 98.32% | -61.88% | 159.37% | 0.78% | 3.05% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M | 47.23M |
COGS % of Revenue | - | - | - | - | 3.5% | 4.92% | 14.38% | 8.29% | 28.88% | - |
Gross Profit | 155.52M▲ 0% | 60.12M▼ 61.3% | 62.02M▲ 3.2% | 97.76M▲ 57.6% | 72.99M▼ 25.3% | 142.63M▲ 95.4% | 48.97M▼ 65.7% | 136.04M▲ 177.8% | 106.32M▼ 21.8% | 109.85M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 96.5% | 95.08% | 85.62% | 91.71% | 71.12% | 69.93% |
Gross Profit Growth % | 79.62% | -61.34% | 3.17% | 57.62% | -25.34% | 95.41% | -65.67% | 177.8% | -21.85% | - |
Operating Expenses | 177.66M | 231.33M | 239.21M | 228.82M | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M | 173.51M |
OpEx % of Revenue | 114.24% | 384.77% | 385.67% | 234.06% | 364.59% | 176.01% | 379.79% | 166.25% | 119.84% | - |
Selling, General & Admin | 32.65M | 40.5M | 46.06M | 42.74M | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M | 38.15M |
SG&A % of Revenue | 21% | 67.36% | 74.27% | 43.72% | 83.3% | 39.29% | 91.25% | 47.89% | 26.19% | - |
Research & Development | 147.23M | 190.83M | 195.31M | 193.2M | 214.58M | 207.03M | 166.58M | 177.19M | 140M | 135.36M |
R&D % of Revenue | 94.67% | 317.4% | 314.89% | 197.62% | 283.67% | 138% | 291.26% | 119.45% | 93.65% | - |
Other Operating Expenses | 2.52M | -247K | -2.16M | -7.12M | -1.8M | -1.92M | -1.56M | -1.62M | 0 | 0 |
Operating Income | -22.14M▲ 0% | -171.21M▼ 673.2% | -177.19M▼ 3.5% | -131.06M▲ 26.0% | -202.79M▼ 54.7% | -121.42M▲ 40.1% | -168.24M▼ 38.6% | -110.58M▲ 34.3% | -72.84M▲ 34.1% | -63.66M▲ 0% |
Operating Margin % | -14.24% | -284.77% | -285.67% | -134.06% | -268.09% | -80.94% | -294.17% | -74.54% | -48.72% | -40.53% |
Operating Income Growth % | 63.12% | -673.18% | -3.49% | 26.03% | -54.73% | 40.13% | -38.57% | 34.28% | 34.13% | - |
EBITDA | -14.91M | -162.01M | -164.88M | -119.1M | -191.54M | -109.55M | -158.6M | -103.04M | -65.67M | -56.57M |
EBITDA Margin % | -9.59% | -269.47% | -265.83% | -121.83% | -253.21% | -73.03% | -277.3% | -69.46% | -43.93% | -36.01% |
EBITDA Growth % | 71.55% | -986.2% | -1.77% | 27.76% | -60.82% | 42.8% | -44.77% | 35.03% | 36.27% | 38.5% |
D&A (Non-Cash Add-back) | 7.23M | 9.2M | 12.31M | 11.96M | 11.26M | 11.87M | 9.64M | 7.54M | 7.17M | 7.09M |
EBIT | -22.14M | -171.21M | -177.19M | -131.06M | -202.12M | -119.76M | -7.63M | -64.91M | -72.84M | -63.66M |
Net Interest Income | 0 | 0 | 3.4M | 800K | 680K | 1.7M | 8.26M | 8.31M | -5.11M | -7.37M |
Interest Income | 0 | 0 | 3.4M | 800K | 680K | 1.7M | 9.69M | 9.42M | 3.4M | 5.93M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1.43M | 1.11M | 8.51M | 13.3M |
Other Income/Expense | 2.52M | -247K | 25.37M | 1.32M | 680K | 1.66M | 159.19M | 44.56M | -2.45M | -7.37M |
Pretax Income | -19.63M▲ 0% | -171.45M▼ 773.6% | -151.81M▲ 11.5% | -129.74M▲ 14.5% | -202.12M▼ 55.8% | -119.76M▲ 40.7% | -9.06M▲ 92.4% | -66.02M▼ 628.9% | -75.29M▼ 14.0% | -71.03M▲ 0% |
Pretax Margin % | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -44.51% | -50.36% | -45.22% |
Income Tax | 0 | -247K | 0 | 0 | 0 | 0 | 0 | 944K | -672K | -672K |
Effective Tax Rate % | 0% | 0.14% | 0% | 0% | 0% | 0% | 0% | -1.43% | 0.89% | 0.95% |
Net Income | -19.63M▲ 0% | -171.45M▼ 773.6% | -151.81M▲ 11.5% | -129.74M▲ 14.5% | -202.12M▼ 55.8% | -119.76M▲ 40.7% | -9.06M▲ 92.4% | -66.97M▼ 639.3% | -74.62M▼ 11.4% | -70.36M▲ 0% |
Net Margin % | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -45.14% | -49.91% | -44.79% |
Net Income Growth % | 66.47% | -773.6% | 11.46% | 14.54% | -55.79% | 40.75% | 92.44% | -639.3% | -11.43% | -26.06% |
Net Income (Continuing) | -19.63M | -171.45M | -151.81M | -129.74M | -202.12M | -119.76M | -9.06M | -66.97M | -74.62M | -70.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.54▲ 0% | -4.19▼ 675.9% | -3.16▲ 24.6% | -2.25▲ 28.8% | -3.18▼ 41.3% | -1.95▲ 38.7% | -0.15▲ 92.3% | -1.07▼ 613.3% | -1.18▼ 10.3% | -1.11▲ 0% |
EPS Growth % | 68.05% | -675.93% | 24.58% | 28.8% | -41.33% | 38.68% | 92.31% | -613.33% | -10.28% | -23.6% |
EPS (Basic) | -0.54 | -4.19 | -3.16 | -2.25 | -3.18 | -1.95 | -0.15 | -1.07 | -1.18 | - |
Diluted Shares Outstanding | 36.1M | 40.93M | 48.08M | 52.44M | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M | 63.45M |
Basic Shares Outstanding | 36.1M | 40.93M | 48.08M | 52.44M | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M | 63.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MGNX Balance Sheet
MacroGenics, Inc. (MGNX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 322.3M | 269.12M | 239.78M | 312.59M | 279.56M | 222.18M | 251.34M | 217.49M | 219.94M | 182.52M |
Cash & Short-Term Investments | 305.12M | 232.86M | 215.76M | 272.53M | 243.62M | 154.35M | 229.81M | 201.67M | 189.91M | 154.23M |
Cash Only | 211.73M | 220.13M | 126.47M | 181.13M | 123.47M | 108.88M | 100.96M | 182.84M | 57.22M | 66.52M |
Short-Term Investments | 93.39M | 12.73M | 89.28M | 91.4M | 120.15M | 45.46M | 128.85M | 18.83M | 132.7M | 87.71M |
Accounts Receivable | 13.64M | 29.58M | 12.74M | 23.08M | 10.39M | 56.22M | 10.37M | 4.31M | 13.37M | 10.43M |
Days Sales Outstanding | 32.02 | 179.6 | 75 | 86.17 | 50.12 | 136.79 | 66.16 | 10.6 | 32.65 | 61.32 |
Inventory | 0 | 0 | 0 | 0 | 4.39M | 1.45M | 1.22M | 0 | 7.91M | 9.5M |
Days Inventory Outstanding | - | - | - | - | 604.16 | 71.72 | 54.2 | - | 66.86 | 68.46 |
Other Current Assets | 383K | 0 | 0 | 0 | 0 | 10.16M | 9.95M | 11.51M | 8.74M | 8.37M |
Total Non-Current Assets | 51.59M | 63.01M | 72.72M | 66.15M | 55.69M | 67.33M | 47.08M | 53.06M | 36.91M | 35.35M |
Property, Plant & Equipment | 49.98M | 56.71M | 68.41M | 61.52M | 54.29M | 56.91M | 45.69M | 42.61M | 35.52M | 33.97M |
Fixed Asset Turnover | 3.11x | 1.06x | 0.91x | 1.59x | 1.39x | 2.64x | 1.25x | 3.48x | 4.21x | 4.31x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.6M | 6.29M | 4.3M | 4.62M | 1.4M | 1.38M | 1.39M | 10.46M | 1.39M | 1.38M |
Total Assets | 373.88M▲ 0% | 332.13M▼ 11.2% | 312.5M▼ 5.9% | 378.74M▲ 21.2% | 335.25M▼ 11.5% | 289.51M▼ 13.6% | 298.42M▲ 3.1% | 261.65M▼ 12.3% | 256.85M▼ 1.8% | 217.87M▲ 0% |
Asset Turnover | 0.42x | 0.18x | 0.20x | 0.26x | 0.23x | 0.52x | 0.19x | 0.57x | 0.58x | 0.63x |
Asset Growth % | 20.12% | -11.17% | -5.91% | 21.2% | -11.48% | -13.64% | 3.08% | -12.32% | -1.84% | 19.57% |
Total Current Liabilities | 49.76M | 59.94M | 45.17M | 50.67M | 74.58M | 48.61M | 56.11M | 55.53M | 43.12M | 95.94M |
Accounts Payable | 2.45M | 4M | 4.31M | 8.03M | 15.5M | 4.9M | 6.44M | 5.01M | 4.79M | 4.29M |
Days Payables Outstanding | - | - | - | - | 2.13K | 242.16 | 286.02 | 148.77 | 40.46 | 38.01 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 4.73M | 0 | 0 | 5.18M | 5.21M |
Deferred Revenue (Current) | 7.2M | 21.72M | 0 | 0 | 0 | 9.99M | 21.65M | 16.32M | 10.92M | 97.09M |
Other Current Liabilities | 1.52M | 1.02M | 10.7M | 4.46M | 20.65M | 29M | 0 | 0 | 22.23M | 18.45M |
Current Ratio | 6.48x | 4.49x | 5.31x | 6.17x | 3.75x | 4.57x | 4.48x | 3.92x | 5.10x | 1.90x |
Quick Ratio | 6.48x | 4.49x | 5.31x | 6.17x | 3.69x | 4.54x | 4.46x | 3.92x | 4.92x | 1.80x |
Cash Conversion Cycle | - | - | - | - | -1.48K | -33.65 | -165.66 | - | 59.05 | 91.77 |
Total Non-Current Liabilities | 24.89M | 29.31M | 36.71M | 32.19M | 21.05M | 98.89M | 89.7M | 98.97M | 158.14M | 100.73M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70M | 31.3M |
Capital Lease Obligations | 0 | 0 | 27.55M | 25.26M | 20.79M | 30.11M | 30.2M | 32.6M | 31.59M | 95.58M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 9.04M | 0 | 8.9M | 0 | 0 |
Other Non-Current Liabilities | 4.05M | 10.31M | 9.15M | 6.93M | 258K | 258K | 258K | 1.97M | 1.05M | 69.44M |
Total Liabilities | 74.64M | 89.25M | 81.87M | 82.86M | 95.63M | 147.5M | 145.81M | 145.6M | 201.25M | 196.68M |
Total Debt | 298K | 0 | 30.57M | 29.25M | 25.47M | 34.83M | 33.97M | 37.46M | 106.76M | 36.51M |
Net Debt | -211.43M | -220.13M | -95.9M | -151.88M | -98M | -74.05M | -66.98M | -145.38M | 49.55M | -30.01M |
Debt / Equity | 0.00x | - | 0.13x | 0.10x | 0.11x | 0.25x | 0.22x | 0.32x | 1.92x | 1.72x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.65x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.53x |
Interest Coverage | - | - | - | - | - | - | -5.33x | -58.21x | -8.56x | -4.78x |
Total Equity | 299.24M▲ 0% | 242.88M▼ 18.8% | 230.63M▼ 5.0% | 295.88M▲ 28.3% | 239.62M▼ 19.0% | 142.01M▼ 40.7% | 152.61M▲ 7.5% | 116.06M▼ 24.0% | 55.59M▼ 52.1% | 21.2M▲ 0% |
Equity Growth % | 11.34% | -18.83% | -5.04% | 28.29% | -19.02% | -40.73% | 7.46% | -23.95% | -52.1% | -188.88% |
Book Value per Share | 8.29 | 5.93 | 4.80 | 5.64 | 4.00 | 2.31 | 2.46 | 1.85 | 0.88 | 0.33 |
Total Shareholders' Equity | 299.24M | 242.88M | 230.63M | 295.88M | 239.62M | 142.01M | 152.61M | 116.06M | 55.59M | 21.2M |
Common Stock | 369K | 424K | 490K | 562K | 613K | 617K | 621K | 628K | 633K | 636K |
Retained Earnings | -312.34M | -490.27M | -642.08M | -771.82M | -973.94M | -1.09B | -1.1B | -1.17B | -1.24B | -1.28B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -61K | -3K | 16K | -7K | -61K | -5K | -6K | 4K | 32K | -27K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MGNX Cash Flow Statement
MacroGenics, Inc. (MGNX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 14.4M | -153.23M | -134.27M | -111.9M | -143.83M | -86.96M | -78.2M | -68.37M | -81.04M | -69.96M |
Operating CF Margin % | 9.26% | -254.88% | -216.48% | -114.46% | -190.14% | -57.97% | -136.74% | -46.09% | -54.21% | - |
Operating CF Growth % | 132.98% | -1163.76% | 12.38% | 16.66% | -28.54% | 39.54% | 10.07% | 12.57% | -18.53% | 79.85% |
Net Income | -19.63M | -171.45M | -151.81M | -129.74M | -202.12M | -119.76M | -9.06M | -66.97M | -74.62M | -70.36M |
Depreciation & Amortization | 7.23M | 8.28M | 10.85M | 11.96M | 11.26M | 11.87M | 9.64M | 7.54M | 5.52M | 6.94M |
Stock-Based Compensation | 14.74M | 16.52M | 19.57M | 20.68M | 23.13M | 20.44M | 18.37M | 29.44M | 14.29M | 9.9M |
Deferred Taxes | 0 | 0 | -25.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 41.62M | 48.39M | 25.09M | -260K | 6.33M | 6.63M | -150.48M | -39.78M | 2.1M | 1.43M |
Working Capital Changes | 12.06M | -6.58M | -12.88M | -14.53M | 17.57M | -6.13M | 53.32M | 1.39M | -28.33M | -17.87M |
Change in Receivables | -10.88M | -15.94M | 16.84M | -10.34M | 12.7M | -45.84M | 45.85M | 6.06M | -9.06M | 117K |
Change in Inventory | 11.83M | -4.63M | -9.63M | 0 | -6.42M | 55K | 230K | -2.19M | -7.91M | -73K |
Change in Payables | -1.54M | 1.55M | 787K | 3.72M | 7.13M | -10.86M | 1.28M | -1.53M | -280K | -2.31M |
Cash from Investing | 77.88M | 56.64M | -79.36M | -7.79M | -36.61M | 70.72M | -80.08M | 149.3M | -114.1M | -78.68M |
Capital Expenditures | -29.4M | -24.95M | -4.29M | -5.91M | -6.2M | -3.62M | -1.76M | -3.71M | -1.91M | -1.73M |
CapEx % of Revenue | 18.91% | 41.51% | 6.92% | 6.04% | 8.2% | 2.42% | 3.08% | 2.5% | 1.28% | 1.1% |
Acquisitions | 0 | 0 | 75.07M | 0 | 0 | 0 | 64K | 0 | 11K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 107.28M | 81.6M | -75.07M | 0 | 0 | 0 | 0 | 40.16M | 0 | 11K |
Cash from Financing | 35.35M | 104.99M | 119.97M | 174.34M | 122.78M | 1.66M | 150.36M | 960K | 69.51M | 69.59M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -157K | 0 | 0 | 0 |
Equity Issued (Net) | 34.2M | 103M | 118.66M | 170.46M | 117.82M | 1.08M | 1.17M | 0 | 129K | 140K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -40K | -260K | 0 | -2.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.14M | 1.99M | 1.31M | 3.89M | 4.96M | 574K | 149.35M | 960K | 69.39M | 69.45M |
Net Change in Cash | 127.63M▲ 0% | 8.4M▼ 93.4% | -93.66M▼ 1214.8% | 54.66M▲ 158.4% | -57.66M▼ 205.5% | -14.59M▲ 74.7% | -7.93M▲ 45.6% | 81.88M▲ 1132.8% | -125.62M▼ 253.4% | -79.05M▲ 0% |
Free Cash Flow | -15M▲ 0% | -178.19M▼ 1088.1% | -138.56M▲ 22.2% | -117.8M▲ 15.0% | -150.03M▼ 27.4% | -90.58M▲ 39.6% | -79.97M▲ 11.7% | -72.08M▲ 9.9% | -82.95M▼ 15.1% | -71.69M▲ 0% |
FCF Margin % | -9.64% | -296.38% | -223.4% | -120.5% | -198.34% | -60.38% | -139.82% | -48.59% | -55.49% | -45.64% |
FCF Growth % | 72.76% | -1088.08% | 22.24% | 14.98% | -27.36% | 39.62% | 11.72% | 9.87% | -15.09% | 0.98% |
FCF per Share | -0.42 | -4.35 | -2.88 | -2.25 | -2.50 | -1.47 | -1.29 | -1.15 | -1.31 | -1.13 |
FCF Conversion (FCF/Net Income) | -0.73x | 0.89x | 0.88x | 0.86x | 0.71x | 0.73x | 8.63x | 1.02x | 1.09x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 944K | 0 | 0 |
MGNX Key Ratios
MacroGenics, Inc. (MGNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -6.91% | -63.25% | -64.12% | -49.28% | -75.49% | -62.76% | -6.15% | -49.85% | -86.95% | -147.8% |
Return on Invested Capital (ROIC) | -12.11% | -232.28% | -168.77% | -70.53% | -106.5% | -86.9% | -164.31% | -294.58% | -144.12% | -132.95% |
Gross Margin | 100% | 100% | 100% | 100% | 96.5% | 95.08% | 85.62% | 91.71% | 71.12% | 69.93% |
Net Margin | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -45.14% | -49.91% | -44.79% |
Debt / Equity | 0.00x | - | 0.13x | 0.10x | 0.11x | 0.25x | 0.22x | 0.32x | 1.92x | 1.72x |
Interest Coverage | - | - | - | - | - | - | -5.33x | -58.21x | -8.56x | -4.78x |
FCF Conversion | -0.73x | 0.89x | 0.88x | 0.86x | 0.71x | 0.73x | 8.63x | 1.02x | 1.09x | 1.02x |
Revenue Growth | 79.62% | -61.34% | 3.17% | 57.62% | -22.63% | 98.32% | -61.88% | 159.37% | 0.78% | 3.05% |
Related:MGNX Dividend History·MGNX Revenue History·MGNX Price History·MGNX P/E History·MGNX Financial Ratios·MGNX Institutional Holders
MGNX SEC Filings & Documents
MacroGenics, Inc. (MGNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MGNX Frequently Asked Questions
MacroGenics, Inc. (MGNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MacroGenics, Inc. (MGNX) reported $157.1M in revenue for fiscal year 2025. This represents a 234% increase from $47.1M in 2011.
MacroGenics, Inc. (MGNX) grew revenue by 0.8% over the past year. Growth has been modest.
MacroGenics, Inc. (MGNX) reported a net loss of $70.4M for fiscal year 2025.
Dividend & Returns
MacroGenics, Inc. (MGNX) has a return on equity (ROE) of -86.9%. Negative ROE indicates the company is unprofitable.
MacroGenics, Inc. (MGNX) had negative free cash flow of $71.7M in fiscal year 2025, likely due to heavy capital investments.